Leonard J - Search Results

1

Clinical use of measurable residual disease in adult ALL: recommendations from a panel of U.S. experts.

Short NJ, Aldoss I, DeAngelo DJ, Konopleva MY, Leonard JT, Logan A, Park JH, Shah BD, Stock W, Jabbour EJ. Short NJ, et al. Among authors: leonard jt. Blood Adv. 2025 Jan 24:bloodadvances.2024015441. doi: 10.1182/bloodadvances.2024015441. Online ahead of print. Blood Adv. 2025. PMID: 39853316

2

Improving Time to Diagnosis and Management of Pediatric Patients with Acute Neurologic Dysfunction.

Spencer SP, Forman NH, Chung MG, Dachenhaus T, Drapeau AI, Gerity C, Iglesias R, Jones JY, Lovett ME, Leonard JC. Spencer SP, et al. Among authors: leonard jc. Jt Comm J Qual Patient Saf. 2024 Dec 16:S1553-7250(24)00379-9. doi: 10.1016/j.jcjq.2024.12.001. Online ahead of print. Jt Comm J Qual Patient Saf. 2024. PMID: 39837707

3

Association of age and performance status with adverse events in older adults with diffuse large B-cell lymphoma receiving frontline R-CHOP therapy: Alliance 151930, a secondary analysis of the phase III trial CALGB 50303.

Morrison VA, Le-Rademacher J, Bobek O, Satele D, Leonard JP, Jatoi A. Morrison VA, et al. Among authors: leonard jp. J Geriatr Oncol. 2025 Jan 13;16(2):102185. doi: 10.1016/j.jgo.2025.102185. Online ahead of print. J Geriatr Oncol. 2025. PMID: 39809075

4

Team resuscitation for paediatrics (TRAP); application and validation of a paediatric resuscitation quality instrument in non-simulated resuscitations.

Flood S, Alletag M, D'Amico B, Halstead S, Mahar P, Rochford L, Markowitz G, Leonard J, Ambroggio L, Neubrand T. Flood S, et al. Among authors: leonard j. Resusc Plus. 2024 Dec 12;21:100844. doi: 10.1016/j.resplu.2024.100844. eCollection 2025 Jan. Resusc Plus. 2024. PMID: 39807283 Free PMC article.

5

Potential Adaptive Introgression From Dogs in Iberian Grey Wolves (Canis lupus).

Sarabia C, Salado I, Fernández-Gil A, vonHoldt BM, Hofreiter M, Vilà C, Leonard JA. Sarabia C, et al. Among authors: leonard ja. Mol Ecol. 2025 Jan 10:e17639. doi: 10.1111/mec.17639. Online ahead of print. Mol Ecol. 2025. PMID: 39791197

6

Neuroinflammatory pathways and potential therapeutic targets in neonatal post-hemorrhagic hydrocephalus.

Schulz LN, Varghese A, Michenkova M, Wedemeyer M, Pindrik JA, Leonard JR, Garcia-Bonilla M, McAllister JP, Cassady K, Wilson RK, Mardis ER, Limbrick DD Jr, Isaacs AM. Schulz LN, et al. Among authors: leonard jr. Pediatr Res. 2024 Dec 26. doi: 10.1038/s41390-024-03733-z. Online ahead of print. Pediatr Res. 2024. PMID: 39725707 Review.

7

Estimation of the spatial variability of the New England Mud Patch geoacoustic properties using a distributed array of hydrophones and deep learninga).

Vardi A, Dahl PH, Dall'Osto D, Knobles D, Wilson P, Leonard J, Bonnel J. Vardi A, et al. Among authors: leonard j. J Acoust Soc Am. 2024 Dec 1;156(6):4229-4241. doi: 10.1121/10.0034707. J Acoust Soc Am. 2024. PMID: 39718359

8

Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trial.

Friedberg JW, Brady MT, Strawderman M, Kahl BS, Lossos IS, Cohen JB, Reagan PM, Casulo C, Averill BL, Baran A, Sutamtewagul G, Barr PM, Leonard JP, Ashton JM, Strang JG, Vega F, Peterson DR, Nastoupil LJ. Friedberg JW, et al. Among authors: leonard jp. EClinicalMedicine. 2024 Nov 27;78:102959. doi: 10.1016/j.eclinm.2024.102959. eCollection 2024 Dec. EClinicalMedicine. 2024. PMID: 39677358 Free PMC article.

9

Developing, Characterizing, and Modeling CRISPR-Based Point-of-Use Pathogen Diagnostics.

Jung JK, Dreyer KS, Dray KE, Muldoon JJ, George J, Shirman S, Cabezas MD, d'Aquino AE, Verosloff MS, Seki K, Rybnicky GA, Alam KK, Bagheri N, Jewett MC, Leonard JN, Mangan NM, Lucks JB. Jung JK, et al. Among authors: leonard jn. ACS Synth Biol. 2025 Jan 17;14(1):129-147. doi: 10.1021/acssynbio.4c00469. Epub 2024 Dec 13. ACS Synth Biol. 2025. PMID: 39670656 Free PMC article.

10

Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial.

TREATT Trial Investigators. TREATT Trial Investigators. Lancet Haematol. 2025 Jan;12(1):e14-e22. doi: 10.1016/S2352-3026(24)00317-X. Epub 2024 Dec 3. Lancet Haematol. 2025. PMID: 39642900 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,010 results

Search Page

Filters